Several iRhythm Technologies Inc. executives allegedly concealed flaws with its heart monitor that left the medical device company exposed to massive liability and degraded its reputation.
iRhythm Technologies IRTC recently announced initial research findings on the post-market, real-world performance of the Zio monitor, IRTC’s next-generation Zio long-term continuous monitoring (LTCM) ...
iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...
SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC) (NASDAQ:IRTC) today announced initial research findings on post-market, real-world performance of Zio ® monitor, its ...
iRhythm, maker of the wearable-and-wireless-but-not-connected Zio heart rate monitoring system, has filed with the SEC to raise up to $86 million in an initial public offering. The Zio patch, ...
In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results